Long-Term Efficacy and Safety of Obecabtagene Autoleucel (obe-cel) in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia ([R/R B-ALL]; Pooled Analysis from ALLCAR19 and FELIX Phase Ib Studies) or Other B-cell Malignancies (ALLCAR19 Extension Study)

医学 临床研究阶段 CD19 内科学 耐火材料(行星科学) B细胞 慢性淋巴细胞白血病 美罗华 CD20 肿瘤科 白血病 淋巴瘤 胃肠病学 临床试验 免疫学 抗原 抗体 生物 天体生物学
作者
Claire Roddie,Eleni Tholouli,Paul Shaughnessy,Elias Jabbour,Aaron C. Logan,Katharine Hodby,Luke Mountjoy,Adrian Bloor,David Irvine,David C. Linch,Kim Orchard,William Wilson,Bilyana Popova,Juliana Dias,Giulia Agliardi,Victoria J. Spanswick,Helen L. Lowe,Marina Mitsikakou,Eftychia Charalambous,Joanna Dawes,Meera Raymond,Yanqing Hu,Wolfram Brugger,Martin Pulè,Jae H. Park,Karl S. Peggs
出处
期刊:Blood [American Society of Hematology]
卷期号:142 (Supplement 1): 2114-2114
标识
DOI:10.1182/blood-2023-180666
摘要

Background: Obe-cel is an autologous CD19 chimeric antigen receptor (CAR) T cell product designed to reduce toxicity and improve persistence through a fast off-rate CD19 binding domain. The clinical activity of obe-cel has been explored in adults with R/R B-ALL in a Phase I study (ALLCAR19, NCT02935257; Roddie C et al. J Clin Oncol 2021) and a Phase Ib/II study (FELIX, NCT04404660; Roddie C et al. J Clin Oncol 2023;41[16 Suppl]:7000). Additionally, obe-cel has been tested in pts with R/R B-cell chronic lymphocytic leukemia (B-CLL) and R/R B-cell non-Hodgkin lymphoma (B-NHL) (ALLCAR19 extension; Roddie C et al. Blood 2022;140[1 Suppl]:7452-3). Pts from the ALLCAR19 and FELIX Phase Ib studies are in long-term follow up (≥22 mos), and the ALLCAR19 extension has been recruiting for 3 years. We report an analysis of long-term efficacy and safety data from the ALLCAR19 and FELIX Phase Ib studies, as well as data from the ALLCAR19 extension. Methods: ALLCAR19 is a multicenter, non-randomized, open-label Phase I study in pts aged ≥16 years with B-cell malignancies. ALLCAR19 initially recruited pts with R/R B-ALL but was then amended (extension study) to also include pts with R/R B-CLL and R/R B-NHL. FELIX is a global, single-arm Phase Ib/II study enrolling pts aged ≥18 years with R/R B-ALL.Study designs have been presented previously. Obe-cel was administered as a split dose in pts with B-ALL (target dose 410 × 10 6 CAR T cells) and pts with CLL (target dose 230 × 10 6 CAR T cells), and as a single infusion in pts with B-NHL (target dose 200 × 10 6 CAR T cells); the pt populations in the two studies were similar. Pts with B-ALL from the ALLCAR19 and FELIX Phase Ib studies are being followed long term for disease progression and survival. For this analysis, data in pts with B-ALL from the ALLCAR19 and FELIX Phase Ib studies were pooled. Data in pts with CLL or B-NHL are presented from the ALLCAR19 extension study. Results: Outcomes in pts with R/R B-ALL: Data in pts with B-ALL were pooled (20 pts from ALLCAR19 [data cut-off Jun 26, 2023] and 16 from FELIX Phase Ib [data cut-off Mar 16, 2023]). The median age of the pooled cohort was 41.5 (range 18 to 74) years and pts had received a median of 3 (range 2 to 6) prior lines of treatment. Twenty-nine of the 36 pts (81%) achieved complete remission (CR)/CR with incomplete hematologic recovery post obe-cel infusions, per investigator assessment. The event-free survival rate was 64% at 6 mos and 49% at 12 mos. With a median follow up of 43 (range 19 to 62) mos, 13/36 pts (36%) remain in remission (8 from ALLCAR19; 5 from FELIX Phase Ib). Among these 13 ongoing responders, 2 (15%) had consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ten of the 11 ongoing responders (91%) who did not receive allo-HSCT still had detectable CAR T cells at the last follow up. All ongoing remissions were measurable residual disease negative at last available assessment. The estimated 2-, 3- and 4-year overall survival rates were 44%, 39% and 39%, respectively. Outcomes in pts with R/R B-CLL/B-NHL: The extension phase of the ALLCAR19 study enrolled 35 pts with B-CLL or B-NHL, of which 26 (B-CLL n=5; B-NHL n=21) received obe-cel (data cut-off Jun 26, 2023). The median age of this combined cohort was 61 (range 39 to 79) years and pts had received a median of 3 (range 2 to 8) prior lines of treatment. At a median follow up of 24 mos, the overall response rate for this cohort was 92% (n=24), and 58% of responders (n=14) were alive without disease progression at last follow up. Late toxicity: Of the 11 long-term R/R B-ALL responders who had not received consolidation allo-HSCT, 10 have ongoing B-cell aplasia. Of the 14 ongoing responders in the R/R B-CLL/B-NHL cohort, 12 have ongoing B-cell aplasia (<20 B cells/µl). Of note, ongoing B-cell aplasia did not correlate with an increased risk of late serious infection. No other long-term toxicity ascribed to obe-cel was reported. Conclusions: The combined analysis of data from the ALLCAR19 and FELIX Phase Ib studies shows long-term efficacy and safety of obe-cel in pts with R/R B-ALL, with approximately one-third of pts still in remission without consolidative allo-HSCT after a median follow up of >3 years. Durable responses of >2 years were also seen in pts with R/R B-CLL and R/R B-NHL.B-cell aplasia was commonly found in long-term follow up of obe-cel recipients, but without a corresponding rise in serious late infections. Obe-cel can effect durable long-term remissions in B-cell malignancies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
脑洞疼应助大胆的擎苍采纳,获得10
2秒前
QY11发布了新的文献求助10
3秒前
称心乐枫完成签到,获得积分10
4秒前
4秒前
Ava应助gluwater采纳,获得10
6秒前
8秒前
lin发布了新的文献求助10
8秒前
leichuang应助称心乐枫采纳,获得20
9秒前
ss13l完成签到,获得积分10
12秒前
bwq关注了科研通微信公众号
12秒前
Noyo发布了新的文献求助10
13秒前
14秒前
偌小梁完成签到,获得积分10
14秒前
ss发布了新的文献求助10
14秒前
阿波完成签到,获得积分10
15秒前
汉堡包应助卡农采纳,获得10
15秒前
16秒前
pluto应助whisper采纳,获得10
17秒前
完美世界应助vic采纳,获得10
17秒前
Holleay123完成签到,获得积分10
18秒前
等等发布了新的文献求助30
19秒前
迟梦乔完成签到,获得积分10
19秒前
21秒前
fei发布了新的文献求助20
21秒前
火星上水杯完成签到,获得积分20
21秒前
21秒前
十二完成签到,获得积分10
22秒前
雪白的稀完成签到,获得积分10
22秒前
nicholasgxz发布了新的文献求助10
23秒前
24秒前
24秒前
24秒前
在水一方应助I Think采纳,获得10
25秒前
追寻南珍发布了新的文献求助30
26秒前
郝好月发布了新的文献求助10
27秒前
卡农发布了新的文献求助10
28秒前
梦之哆啦发布了新的文献求助10
28秒前
梁三柏应助13654135090采纳,获得10
29秒前
30秒前
研友_8YoVDn完成签到,获得积分10
30秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Pharmacogenomics: Applications to Patient Care, Third Edition 800
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3082549
求助须知:如何正确求助?哪些是违规求助? 2735847
关于积分的说明 7539036
捐赠科研通 2385432
什么是DOI,文献DOI怎么找? 1264844
科研通“疑难数据库(出版商)”最低求助积分说明 612830
版权声明 597685